Mechanism Review
Want us to review the evidence behind your mechanism?
See examples below and contact us.
A new drug pair needs its own evidence.
✓ Supported
Tested pair
Versus A alone, in this lab test.
? Not supported
New pair
This study does not tell us.
A = imatinib · B = chloroquine · C = a proposed new drug.
“Not supported” means not shown by this study. It does not mean the new pair cannot work.
Sample case, not client work. Scientific review pending.
Why this matters
The study already checked cells after the drugs were removed. The missing piece is evidence for the new drug pair.
Our next-step advice: check the new pair’s data first. If key evidence is missing, fill that gap before funding a larger animal study.
A proposed next step for this sample case.
Start with one figure
- 1Check its claims
- 2Trace the sources
- 3Recommend next steps
You get a marked figure, checked claims with sources, and a short written recommendation.
We agree on the scope and fee before work starts.
See the evidence and review
This is a focused sample, not a full review of a drug.
Claim register
Evidence, conditions and revised wording
- Finding
- Imatinib + chloroquine reduced long-term culture-initiating cell (LTC-IC) output about 4.5-fold versus imatinib alone, with growth factors.
- Conditions
- Three CML samples; imatinib 2 µM + chloroquine 10 µM for six days, then washout and long-term culture. Figure 8D and methods ↗
- Interpretation
- Functional evidence after drug removal. It does not establish stem-cell eradication in patients.
- Claim
- “These results justify efficacy testing of our combination.”
- Missing evidence
- Does our compound affect the intended pathway and reduce durable CML cell function at feasible exposure, with separation from normal-cell toxicity? No candidate data were supplied.
- Use instead
- “The published combination supports the rationale. Our compound’s exposure and functional evidence will determine the next study.”
Decision memo
Proposed study and decision limits
- Check first
- Review existing candidate data before ordering more experiments. If the bridge is already supported, assess the efficacy study on that evidence.
- If missing
- Run a focused exposure–response study: candidate alone, imatinib alone and the combination, with vehicle controls. Link pathway activity to post-washout CML function and normal blood-forming cell function at matched exposures.
- Advance when
- Mechanism-consistent activity and functional benefit over either drug alone occur at a feasible exposure, with a credible normal-cell margin.
- Hold when
- The effect requires implausible exposure or tracks general toxicity. More efficacy work alone would not resolve that problem.
Illustrative recommendation. Agree assays, exposure benchmarks and decision thresholds from the actual compound and intended model.
Sources and review status
This focused example builds on C03/C04/C08 of sample MD-MER-CML-AUTO-002, v2.2. It is not a full literature review or asset assessment. Bellodi’s study already includes washout and normal-cell experiments; neither establishes a new compound’s therapeutic margin. The supplement has not been independently appraised here.
Biomarker interpretation: LC3 accumulation alone cannot distinguish increased autophagosome formation from blocked clearance. Select flux controls for the compound’s mechanism; do not treat a static LC3 signal as direct target engagement.
The paper’s 2013 correction concerns Figure 1D, not the Figure 8 result used here. Prepared with AI assistance. Independent review remains open: mechanism and exposure (H2), functional assays (H3), experiment priorities (H5), and final wording and figure (H6). The full sample’s other review gates remain open.
What do you want to find out?
Shashank Shrishrimal, Ph.D.Reads every inquiry
Experience in drug discovery, drug development and biomarker analysis.
Or email Shashank.